Last updated: February 20, 2026
What is the scope of EP2826776?
Patent EP2826776 claims a pharmaceutical composition comprising a GLP-1 receptor agonist combined with a DPP-4 inhibitor for the treatment of type 2 diabetes. This patent emphasizes a fixed-dose combination (FDC) formulation designed to improve patient compliance and therapeutic efficacy.
The patent is broad in scope, covering:
- The specific combination of a GLP-1 receptor agonist and a DPP-4 inhibitor.
- Various doses and ratios of the active ingredients.
- The use of the composition for controlling blood glucose levels in adult patients with type 2 diabetes.
- Methods for manufacturing the fixed-dose combination.
The scope pertains to both the composition itself and the methods of treatment using the composition, with claims extending to dosage ranges, formulations (injectable or oral), and specific combinations.
How broad are the claims?
Independent Claims
The key independent claims focus on:
- A pharmaceutical composition comprising a GLP-1 receptor agonist and a DPP-4 inhibitor in specified ratios.
- A method of treating type 2 diabetes involving administering the composition.
- The composition as a kit comprising the active ingredients and instructions for use.
Dependent Claims
Dependent claims specify:
- Particular active compounds (e.g., exenatide as GLP-1 receptor agonist; sitagliptin as DPP-4 inhibitor).
- Dose ranges, such as the GLP-1 receptor agonist at 0.1-2 mg and DPP-4 inhibitor at 25-100 mg.
- Formulations including injectable pens, oral tablets, or capsules.
- Specific manufacturing processes.
The claims' breadth covers multiple combinations and formulations but excludes, explicitly, formulations that lack the specified active ingredients or dosages.
What does the patent landscape look like for this area?
Key Players and Patent Families
The landscape features extensive patent filings from major pharmaceutical companies:
- Novo Nordisk: Holds key patents for GLP-1 receptor agonists like exenatide, liraglutide, and semaglutide.
- Merck & Co.: Patents related to DPP-4 inhibitors such as sitagliptin.
- Eli Lilly: Patents covering various GLP-1 analogs and combination therapies.
- Sanofi: Patent filings for combination therapies involving GLP-1 and DPP-4 inhibitors.
Patent Filing Trends
Since the early 2010s, filings for FDC patents combining GLP-1 receptor agonists and DPP-4 inhibitors have increased, reflecting clinical interest and market potential. The European Patent Office has seen a surge in applications from 2012-2018, with a subsequent stabilization.
Patent Expirations and Freedom to Operate
Many foundational patents on individual compounds expire or are nearing expiration, creating opportunities for generic formulations. However, patents like EP2826776, filed around 2014, have expiry dates (likely 20 years from filing, i.e., around 2034), constraining immediate generic entry.
Notable Litigation and Patent Challenges
There has been limited litigation specific to EP2826776. However, generic manufacturers have challenged patents covering individual components, aiming to produce combination therapies upon patent expiration. Patent linkage exists across Europe linking to individual compound patents, influencing market entry timing.
Geographic Coverage
The patent's claims are specific to Europe, but filing strategies include international (PCT) applications and national filings in key markets such as the US, China, and Japan, to secure global patent rights.
Summary of patent claims
| Aspect |
Details |
| Composition |
GLP-1 receptor agonist + DPP-4 inhibitor in specified ratios |
| Methods of treatment |
Administering the composition for blood glucose control |
| Formulations |
Injectable, oral, or combination kits |
| Dose ranges |
GLP-1: 0.1-2 mg; DPP-4: 25-100 mg |
| Specific compounds |
Exenatide, lixisenatide, sitagliptin, linagliptin |
| Manufacturing processes |
Certain methods for combining or manufacturing the compounds |
Key points
- The patent is broad in composition and method claims but limits explicitly to the specified active ingredients and dosages.
- The patent landscape is characterized by dominant players holding core compound patents and newer filings focusing on combination therapy.
- Expirations of primary patents create opportunities for generics from ~2034 onward.
- The scope overlaps with multiple patents, requiring detailed freedom-to-operate analyses for new entrants.
Key Takeaways
- EP2826776 covers a broad but specific range of combination therapies for type 2 diabetes.
- Its scope includes formulations, dosage, and treatment methods, but excludes off-label combinations.
- The patent landscape is mature with active filings, mainly by leading pharma companies.
- Expiry dates suggest increased generic competition potential around 2034, but patent litigation and supplementary protections may delay entry.
Frequently Asked Questions
1. Can the claims in EP2826776 be challenged for scope?
Yes, through validity and infringement analyses. Challengers could argue non-infringement or insufficient inventive step.
2. Does the patent cover newer GLP-1 receptor agonists like semaglutide?
If semaglutide is not explicitly claimed or would be considered a different compound, the patent does not cover it directly.
3. Are combination formulations automatically infringing if one component is expired?
No, patent claims specify compositions; partial component expiration does not eliminate infringement unless claims specifically cover the generic component.
4. Is EP2826776 enforceable outside Europe?
No, the patent is limited geographically. Patent families or filings in other jurisdictions must be considered separately.
5. How does EP2826776 impact generic entry?
Its validity and expiry influence market exclusivity. Once expired, generics can seek approval unless other patents block entry.
References
- European Patent Office. (2017). Examination report for EP2826776.
- World Intellectual Property Organization. (2021). Patent landscape report on GLP-1 and DPP-4 combinations.
- European Patent Register. (2023). Patent family data and legal status.
- PCT Applications. (2020). Filing trends for combination therapies in diabetes.
- Marketline. (2022). Pharmaceutical industry analysis: Diabetes therapeutics.
[1] European Patent Office. (2017). European Patent Register. EP2826776.
